Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objectives The primary objective was to compare the vaginal bleeding pattern during administration of tibolone and low‐dose continuous combined estradiol plus norethisterone acetate (E 2/NETA). The secondary objectives were efficacy on vasomotor symptoms and vaginal atrophy. Design A randomised, double‐blind, double‐dummy, group comparative intervention trial. Setting Multicentre study executed in 32 centres in 7 European countries. Sample Five hundred and seventy‐two healthy symptomatic postmenopausal women, aged 45–65 years. Methods Participants were randomised to receive 2.5 mg tibolone or 1 mg 17β estradiol plus 0.5 mg norethisterone acetate (E 2/NETA) daily for 48 weeks. Main outcome measures Prevalence of vaginal bleeding, hot flushes and adverse events. Results The incidence of bleeding was significantly lower in the tibolone group during the first 3 months of treatment (18.3 versus 33.1%; P < 0.001) when compared with the E 2/NETA group. This effect on the bleeding pattern was sustained throughout the study, although reaching statistical significance again only in 7–9 months of treatment (11 versus 19%; P < 0.05). In both treatment groups, vasomotor symptoms and vaginal atrophy were significantly reduced to a similar extent when compared with baseline. The prevalence of breast pain/tenderness was significantly lower with tibolone compared with E 2/NETA (3.2 versus 9.8%; P < 0.001). Conclusion Tibolone reduces menopausal symptoms to a similar extent as conventional low‐dose continuous combined hormone therapy but causes significant less vaginal bleeding in the first 3 months of treatment. This constitutes an important argument for woman adherence to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
Cited by
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“The incidence of breast tenderness is low (around 3%), (201, 202), and neither mammographic density nor invasive breast cancer was increased; however, the risk of colon cancer was decreased (199, 201).”
BackgroundMenopausal hot flushes and night sweats: where are we now?
Archer, D. F., Sturdee, D. W., Baber, R., de Villiers, T. J., Pines, A., Freedman, R. R., Gompel, A., Hickey, M., Hunter, M. S., Lobo, R. A., et al. (2011) · Climacteric · doi:10.3109/13697137.2011.608596 · Cited by 185
Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women
Mirkin, S., Komm, B. S., Pan, K., & Chines, A. A. (2013) · Climacteric · doi:10.3109/13697137.2012.717994 · Cited by 83
Metadata
- Authors
- Hammar, M., Van De Weijer, P., Franke, H., Pornel, B., Von Mauw, E., Nijland, E., & TOTAL Study Investigators Group
- Venue
- BJOG: An International Journal of Obstetrics & Gynaecology
- Publisher
- Wiley
- Published
- 2007-11-08
- Volume
- 114
- Issue
- 12
- Pages
- 1522-1529
- ISSN
- 0306-5456 (ISSN-L)
- 1470-0328
- 1471-0528
- OpenAlex
- W2105801978
- Cited by
- 55
- References
- 1
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. https://app.cochat.ai/papers/10.1111/j.1471-0528.2007.01537.x
- The paper
- Hammar, M., Van De Weijer, P., Franke, H., Pornel, B., Von Mauw, E., Nijland, E., & TOTAL Study Investigators Group. (2007). Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/j.1471-0528.2007.01537.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.